MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
2.040
+0.120
+6.25%
After Hours: 2.070 +0.03 +1.47% 19:46 06/21 EDT
OPEN
1.870
PREV CLOSE
1.920
HIGH
2.070
LOW
1.870
VOLUME
159.03K
TURNOVER
0
52 WEEK HIGH
7.75
52 WEEK LOW
1.550
MARKET CAP
53.89M
P/E (TTM)
-2.2023
1D
5D
1M
3M
1Y
5Y
Immix Biopharma Inc: Statement of changes in beneficial ownership of securities
Press release · 1d ago
Weekly Report: what happened at IMMX last week (0610-0614)?
Weekly Report · 6d ago
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma, Inc. Will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Immix is a clinical-stage biopharmaceutical company. The company is developing cell therapies in autoimmune disease to treat cancer and other diseases.
Barchart · 6d ago
Immix Biopharma Shareholders Back Growth and Governance Changes
TipRanks · 06/14 22:00
RENOVORX APPOINTS RYAN WITT AS SENIOR VICE PRESIDENT, HEAD OF CORPORATE STRATEGY AND PARTNERSHIPS
Reuters · 06/10 12:30
Weekly Report: what happened at IMMX last week (0603-0607)?
Weekly Report · 06/10 12:04
Weekly Report: what happened at IMMX last week (0527-0531)?
Weekly Report · 06/03 12:07
Weekly Report: what happened at IMMX last week (0520-0524)?
Weekly Report · 05/27 12:14
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.